Laurel Sapp, APRN
Family · Vidalia, GANPI 1467930156
Payments from drug & device makers
Across 372 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$966
- Merck$520
- AstraZeneca$464
- GSK$442
- Regeneron Healthcare Solutions, Inc.$426
- Novo Nordisk$398
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,925100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $966 |
| Merck | 30 | $520 |
| AstraZeneca | 21 | $464 |
| GSK | 33 | $442 |
| Regeneron Healthcare Solutions, Inc. | 22 | $426 |
| Novo Nordisk | 32 | $398 |
| Dexcom, Inc. | 19 | $351 |
| Boehringer Ingelheim | 23 | $321 |
| Amgen | 15 | $242 |
| Lilly USA, LLC | 11 | $170 |
| Grifols USA, LLC | 7 | $154 |
| Sanofi-aventis U.S. LLC | 9 | $140 |
| Corcept Therapeutics | 6 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $121 |
| Esperion Therapeutics, Inc. | 8 | $119 |
| Kowa Pharmaceuticals America, Inc. | 8 | $109 |
| Idorsia Pharmaceuticals US Inc | 6 | $100 |
| Pfizer | 6 | $98 |
| Sanofi | 4 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Exact Sciences | 4 | $62 |
| Novartis | 3 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Kaleo, Inc. | 2 | $28 |
| Eisai Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 2 | $17 |
| Bayer | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,925 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 301 | $323,400 |
| OzempicSemaglutide | 275 | $303,868 |
| FarxigaDapagliflozin Propanediol | 101 | $70,277 |
| XareltoRivaroxaban | 64 | $46,458 |
| JardianceEmpagliflozin | 62 | $44,919 |
| EliquisApixaban | 62 | $43,400 |
| TrulicityDulaglutide | 23 | $33,324 |
| JanuviaSitagliptin Phosphate | 36 | $32,114 |
| LinzessLinaclotide | 30 | $32,005 |
| WegovySemaglutide | 14 | $21,335 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $19,756 |
| SymbicortBudesonide/Formoterol Fumarate | 63 | $18,002 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $16,959 |
| RybelsusSemaglutide | 14 | $15,074 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $170 | $356,724324 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $398 | $340,277303 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $464 | $100,442181 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $321 | $58,90187 claims |
| Johnson & JohnsonXarelto | $15 | $46,45864 claims |
| PfizerEliquis | $98 | $43,40062 claims |
| MerckJanuvia, Janumet | $520 | $42,54255 claims |
| AbbVieLinzess, Synthroid | $966 | $41,444139 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $442 | $31,67152 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $109 | $10,31111 claims |
| NovartisEntresto | $57 | $8,30612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $3,371372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Vidalia
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.